Zennova Pharmaceuticals Group is an international pharmaceutical company registered in Cayman, driven by innovative research and development. We have excellent product development technology and world-class quality products. We provide world-class medicines of superior value to our patients. Our strategy focuses on global research and development, manufacturing in China, and serving global markets. We focus on four major therapeutic areas: ophthalmology, virology, cardiovascular and oncology.
We currently have R&D and production facilities in New York, New Jersey, and Chengdu, China. Our State-of-The-Art pharmaceutical manufacturing facility located in Chengdu Tianfu International Biotown is designed to qualify US FDA, EU EMA, and China cGMP standards. It is set up to meet world-class quality standard for all dosage forms of medicines. It includes various oncology drugs, sterile eye drops products, central nervous system medicines, and other complex formulation drugs. Our products are to be sold to the US, Europe, China and other global markets.
Mr. Dahai Guo is the co-founder, Chairman & CEO of Zennova Pharma Group. He is a seasoned executive and successful series entrepreneur who has served as Chairman & CEO over 7 pharmaceutical companies.
In his successful earlier career, he was the co-Founder & CEO of series successful companies such as PuraCap Pharmaceutical LLC. (in US), Chairman & CEO of Humanwell PuraCap Pharmaceutical (Wuhan) Ltd. (in China, CEO of Epic Pharma (in US), CEO of Puracap International LLC. (former Blu Pharmaceuticals Inc.) & CEO of Humanwell USA LLC. etc.
Under Mr. Guo’s leadership, Zennova & PuraCap Pharmaceutical with its affiliated companies are one of the leaders in specialty pharma & healthcare industry, who has developed, manufactured and marketed broad range of Branded Rx, Generic Rx and OTC pharmaceutical products in US, China & the global markets. PuraCap & affiliates have over 80 different drugs and over 500 SKUs selling in US, China, Canada and other countries. It has four US FDA inspected manufacturing and packaging facilities in US & China.
Founded by Mr. Guo, Humanwell PuraCap Pharmaceuticals Inc. has grown to become one of the largest and renowned softgel companies in the world. It has been recognized and awarded as “Top Ten leading Chinese pharmaceutical company in global market” & “China’s Top 100 Gazelle Companies” award.
Mr. Guo has MBA from Cornell University and M.S. of Biology from Rutgers, the State University of New Jersey, BS from Xiamen University. He also completed distinguish Six-Sigma Black Belt training, awarded by America Society for Quality. Mr.Guo is awarded the “ Distinguished Alumni Award by Xiamen University”. Mr. Guo is the founding Chairman of BioKatalyst Corp, a non-profit organization whose invited-only members are the top management elites of Chinese Americans crossing healthcare industry.
Chief Scientist&Vice President&Vice President
33 years of experience in drug development and technical management
Dr. Adam Feng is the co-founder & Chief Scientific Officer at Zennova Pharma Group. Dr. Feng is recognized as one of the most experienced experts in pharmaceutical research & development, especially the advance technology of drug formulation & complex generic drug development. He has served as the Head of R&D in several global pharmaceutical companies.
Dr. Feng has extensive experience in pharmaceutical product development, new technology innovation, people management and project management. Since the early 1990s, he has worked in many world-renowned pharmaceutical companies including Merck, TEVA, and Takeda in the United States where he was the Director of R&D. When Dr. Feng worked as the Sr. VP and Head of Global R&D in PuraCap Pharmaceuticals, he directly managed the company's four research and development centers in US & China. Under his leadership, there were over 60 preion drugs developed in various dosage forms, including tablets, granules, soft capsules etc. It is the largest portfolio of FDA drug pipeline among all Chinese Pharmaceutical companies.
Dr. Feng has obtained more than 20 patents from US, China and globally in broad fields of drug formulation, drug analysis, process development, etc. He has a diverse and successful experience in innovative new drug (NDA) and generic drug (ANDA) development and product life cycle management expertise.
Through 26-year industry experience including senior management role, Dr. Feng has an in-depth understanding of FDA regulations, cGMP compliance and DEA (United States Drug Control Agency) compliance. Dr. Feng has led numerous new drug development projects in his previous careers. He achieved over 50 drug approval from US FDA. This accomplishment ranks him as one of the top scientist in Chinese pharmaceutical industry. Especially, two innovative new drugs NDAs (Colcrys for the treatment of gout and Fibricor for the reduction of triglycerides) were quickly reach over US$500 million in sales after they were approved and launched in US market. Dr. Feng also pioneers in complex nano-particle formulation products and multiparticulate controlled-release products.
Dr. Feng received his PhD degree in pharmaceutics from Long Island University, and his BS degree in Chemistry from Beijing Normal University. He was honored with the “3551 Leading Excellent Talent Award" in China.
Vice President of Business Development
38 years of successful commercial development experience in innovative and non patented pharmaceutical industries
Graduated from the Department of Chemistry/Natural Sciences at Akron University in the United States, with two MBA degrees from Philly Dickens University; Having 36 years of rich experience in the pharmaceutical industry and senior commercial development experience, including in the fields of raw materials, small and large molecule formulations, and generic drugs; Completed 9 company mergers and acquisitions; And has rich experience in various pharmaceutical products and ANDA cooperation and mergers and acquisitions; Participated in multiple matchmaking negotiations for startups and CDMO; Manage multiple business departments and lead multiple strategic planning processes; We have deep network relationships with pharmaceutical companies in the global market, including Europe, the United States, India, Israel, and China.
CFO
With more than 20 years of senior investment management experience in the financial industry
MBA from Harvard University, undergraduate degree from the University of Rochester
With more than 20 years of senior investment management experience in the financial industry, he has been responsible for more than $7 billion in financial assets and mergers and acquisitions at Merrill Lynch and Salomon Brothers (now Citibank).
He has served as CFO and director of several high-tech companies
Senior angel investor and founder of AngelVest Fund. He serves on the board of directors of the Harvard University Alumni Angel Investors Association
COO
With more than 30 years of management experience in the pharmaceutical industry
Ph.D. in Economics, UBI, Belgium; Ph.D. in Business Administration, Tongji University
With more than 30 years of management experience in the pharmaceutical industry, he has served as CEO, general manager, president and other senior management positions in large pharmaceutical companies
He has rich and successful experience in pharmaceutical marketing, selling to China, United States, Japan, Korea, Europe and other countries
Successfully led the annual sales of single products to exceed 7 billion yuan
Assisted Neptunus Biologics, Neptune Technology and other companies in IPO
Manage a number of enterprises, through the United States FDA, EU and other certifications, and product export
Chief Financial Officer
David R. Taft, Ph.D. is Professor of Pharmaceutics at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences at Long Island University.
Professor Taft’s primary research area is pharmacokinetics, and his work involves a combination of in vitro, in vivo, and in silico techniques. Professor Taft has collaborated with numerous companies on projects ranging from characterizing renal drug excretion in rat-kidney models to drug formulation evaluation in preclinical and clinical studies. His laboratory is widely recognized for its work using isolated organ systems as tools to study drug disposition, most notably the isolated perfused kidney model. For the past several years, his research has focused on physiologically based pharmacokinetic (PBPK) modeling and simulation. Professor Taft is a member of the Editorial Advisory Boards of the Journal of Pharmaceutical Sciences (2003-present) and Drug Development and Industrial Pharmacy (2005-present). He serves on the Editorial Board for the journal Current Drug Discovery Technologies (2007-present) the AAPS Introductions to the Pharmaceutical Sciences book series. He is a past recipient of the AACP New Investigators Award, the Long Island University David Newton Award for Excellence in Teaching, the AAPS New Investigator Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, and the University of Connecticut School of Pharmacy Distinguished Alumni Award. He is also an AACP Academic Leadership Fellow.
Robert A. Bellantone, Ph.D. is the founder, President and Chief Scientific Officer of Physical Pharmaceutica LLC, where he oversees the development of specialized testing and complex dosage form development, including ophthalmics and amorphous solid forms
Dr. Bellantone earned a B.S. in pharmacy and a Ph.D. in physics. He has over 25 years of pharmaceutical research and development experience that integrates his diverse background in pharmacy, pharmaceutics, formulation material science, biopharmaceutics and pharmacokinetics, mathematics and numerical analysis for modeling and analyzing complex systems. He is the author or co-author of over 110 peer-reviewed research articles and presentations at national meetings and the author of a book chapter on amorphous solids. He has conducted three funded research projects for the U.S. FDA. In addition, he is the named inventor of nine awarded U.S. patents and two pending applications.
Relying on patented technology we independently research and develop high-end innovative drugs of complex formulations.
US pharmaceutical technology and international quality standards, conduct global CDMO business.
Seek cooperation and develop innovative drugs for high barriers. Deeply cooperate with global research institutions and excellent pharmaceutical companies to develop innovative drugs .
Be a world-class pharmaceutical company operating globally
Produce innovative & high-quality medicines for patients.
Innovation, Responsibility, Integrity and Win-win
Technology driven, excellent quality
Innovation For Better Medicine